We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In a win for Daiichi Sankyo’s big pivot to oncology, the Japanese drugmaker has snatched its first U.S. cancer nod since 2011—and it’s also the first FDA-approved drug for a rare joint tumor.